Veteran consumer health and FMCG strategist to lead preventive wellness and nutrition portfolio expansion through innovation and modern trade channels
The decision now moves to the European Commission, with a final ruling expected by the third quarter of 2026
The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy
With standout ADC and t-cell engager response data across hard-to-treat cancers
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
Net profit stood at Rs. 921 crore for the quarter, while Europe revenues surged 30.2% YoY to Rs. 2,795 crore
SFDA nod marks company’s strategic entry into high-value specialty oncology injectables as it targets expanding stem cell transplant and haemato-oncology market in the GCC region
Approved product is therapeutically equivalent to Synthroid of AbbVie and is indicated for the treatment of congenital or acquired hypothyroidism
Eris Lifesciences posts sharp profit surge in FY26 driven by strong diabetes portfolio growth
Company’s EBITDA grew 29.3 per cent to Rs. 290.4 crore, while PAT rose 36.4 per cent to Rs. 137.7 crore
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
